Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) is a specialty pharmaceutical company focused on men's health, best known for JATENZO, its FDA-approved oral testosterone replacement therapy. The company reached the public markets through a SPAC business combination, with its shares trading on Nasdaq as the surviving post-merger entity in the healthcare and specialty pharmaceutical sector. The Form 8-K filed on August 27, 2021, accession number 0001213900-21-045339, represents a current report submitted as part of the company's ongoing SEC disclosure obligations following deal close. For comprehensive filing histories, sponsor profiles, and SPAC deal analytics covering CRXT and thousands of other transactions, sign up for full data access at SpacDesk.